MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Home・Aandelen Lijst・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Gesloten

1.33 2.31

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.29

Max

1.38

Belangrijke statistieken
By Trading Economics
Inkomsten	2.7M -24M
EPS	-0.354
Werknemers	49
EBITDA	-5.3M -28M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+103.82% upside

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-624K 80M
Vorige openingsprijs	-0.98
Vorige sluitingsprijs	1.33

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

1.43 / 1.6 Steun & Weerstand

Pliant Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 apr 2026, 23:26 UTC

Populaire aandelen

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 apr 2026, 20:41 UTC

Belangrijke Marktbewegers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 apr 2026, 23:49 UTC

Marktinformatie

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline After Hitting Record High -- Market Talk

16 apr 2026, 23:33 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 apr 2026, 22:51 UTC

Marktinformatie

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 apr 2026, 22:08 UTC

Winsten

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 apr 2026, 22:06 UTC

Winsten

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Tech, Media & Telecom Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

16 apr 2026, 20:50 UTC

Marktinformatie

Winsten

Health Care Roundup: Market Talk

16 apr 2026, 20:49 UTC

Winsten

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 apr 2026, 20:43 UTC

Winsten

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:40 UTC

Marktinformatie

Winsten

Global Equities Roundup: Market Talk

16 apr 2026, 20:40 UTC

Marktinformatie

Winsten

Netflix Says Engagement Quality Hits New High -- Market Talk

16 apr 2026, 20:30 UTC

Populaire aandelen

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 apr 2026, 20:25 UTC

Winsten

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 apr 2026, 20:23 UTC

Winsten

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 apr 2026, 20:19 UTC

Winsten

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 apr 2026, 20:17 UTC

Winsten

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 apr 2026, 20:16 UTC

Winsten

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Vergelijking

Prijswijziging

Pliant Therapeutics Inc Prognose

Koersdoel

By TipRanks

103.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.67 USD 103.82%

Hoogste 3 USD

Laagste 2 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Pliant Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Pliant Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.43 / 1.6Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.